Many DNA sequences, for example, influence gene activity by altering a chromosome’s 3D shape, either restricting or easing access for the machinery that does the transcription.

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, accelerating a push into experimental cardiovascular therapies.